-
- Posts: 120
- Joined: Fri Jan 26, 2007 5:26 pm
I've recently started a new job at a peptide manufacturer and the majority of the validations I am overseeing are for customer's peptides where there is no reference material (i.e. these are new chemical entities). I'm looking for some opinions/anecdotes/etc regarding the use of ICH regulations for accuracy, specifically 4.1.1b (comparison of results versus a 2nd well-characterized procedure) and 4.1.1c (infer once linearity, precision, specificity have been shown). I'm not sure how acceptable these methods of determining accuracy are in the eyes of an auditor. Any input or opinions you could provide would be most helpful.
Thank you.
